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a b s t r a c t
Purpose/objectives: SBRT is used to treat oligometastatic or unresectable primary abdominal malignan-
cies, although ablative dose delivery is limited by proximity of organs-at-risk (OAR). Stereotactic, mag-
netic resonance (MR)-guided online-adaptive radiotherapy (SMART) may improve SBRT’s therapeutic
ratio. This prospective Phase I trial assessed feasibility and potential advantages of SMART to treat
abdominal malignancies.
Materials/methods: Twenty patients with oligometastatic or unresectable primary liver (n = 10) and non-
liver (n = 10) abdominal malignancies underwent SMART. Initial plans prescribed 50 Gy/5 fractions (BED
100 Gy) with goal 95% PTV coverage by 95% of prescription, subject to hard OAR constraints. Daily real-
time online-adaptive plans were created as needed, based on daily setup MR-image-set tumor/OAR
‘‘anatomy-of-the-day” to preserve hard OAR constraints, escalate PTV dose, or both. Treatment times,
patient outcomes, and dosimetric comparisons between initial and adaptive plans were prospectively
recorded.
Results: Online adaptive plans were created at time of treatment for 81/97 fractions, due to initial plan
violation of OAR constraints (61/97) or observed opportunity for PTV dose escalation (20/97). Plan adap-
tation increased PTV coverage in 64/97 fractions. Zero Grade  3 acute (<6 months) treatment-related
toxicities were observed.
Discussion: SMART is clinically deliverable and safe, allowing PTV dose escalation and/or simultaneous
OAR sparing compared to non-adaptive abdominal SBRT.
 2017 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 126 (2018) 519–526
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Stereotactic body radiation therapy has revolutionized
treatment of medically inoperable cancers [1,2]. Investigation of
varying fractionation schedules in disease sites such as the lung
demonstrated a critical biologically equivalent dose of approxi-
mately 100 Gy, under which local control and survival outcomes
were significantly poorer [3,4]. More recently, the role of stereo-
tactic radiation for unresectable pancreatic cancer and limited
abdominal metastases has been further investigated [5–7].
Unfortunately, the proximity of gastrointestinal viscous struc-
tures and their positional uncertainty has often limited dose
[6,8].
It is well known that both intra-fraction respiratory motion and
inter-fraction physiologic organ motion contribute to inherent
positional uncertainty of abdominal structures [9,10]. Compared
to traditional computed-tomography (CT)-based strategies, mag-
netic resonance (MR) image-guided radiation therapy (IGRT) con-
fers superior soft tissue definition that is potentially
advantageous in abdominal disease sites, enabling daily imaging
of sufficient quality to permit daily plan adjustments in response
to inter-fraction organ motion [11,12]. Such online adaptive radia-
tion therapy (ART) has been previously described by our institution
for conventionally-fractionated RT [13]. Recently, our group
modeled potential advantages of stereotactic, MR-guided online-
adaptive radiotherapy (SMART) for abdominal disease sites and
found it allowed PTV dose escalation and/or simultaneous
improvements in OAR sparing when compared with non-
adaptive SBRT [14].
https://doi.org/10.1016/j.radonc.2017.11.032
0167-8140/ 2017 The Authors. Published by Elsevier Ireland Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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To evaluate the feasibility and safety of SMART for abdominal
disease sites, we conducted a prospective Phase I clinical trial of
this technique for oligometastatic and unresectable primary liver
and non-liver abdominal malignancies. The primary endpoint
was feasibility, defined by delivery of adaptive treatment in <80
min on-table time for >75% of cases. We hypothesized that SMART
would be clinically feasible and deliver ablative radiation doses
with low rates of gastrointestinal toxicity.
Methods
Eligibility
Washington University’s Institutional Review Board approved
this protocol (NCT02264886). Patients with oligometastatic or
unresectable primary liver or non-liver-abdominal malignancies
who were considered technical and clinical candidates for SBRT
were prospectively enrolled. Oligometastatic disease was defined
as 3 progressive disease sites; patients were eligible if 1 site
was amenable to abdominal SBRT. Patients were 18-years-old
and had Karnofsky Performance Status (KPS) 70%, capacity to
provide consent, and disease of solid-tumor (non-hematologic)
categorization, excluding small-cell cancers. All patients were
required to complete any systemic therapy 1 week prior to
planned start of SMART, with no plans to initiate systemic therapy
for 1 week following completion of SMART. Patients were
excluded for prior history of radiotherapy within the projected
treatment field, current receipt of other investigational agents,
uncontrolled intercurrent illness, pregnancy and/or breastfeeding,
or medical contraindication to undergoing MR-imaging.
Simulation and initial plan
Details of the initial treatment planning process, simulation,
MR-IGRT treatment device, imaging characteristics and dedicated
MR-IGRT treatment planning system (TPS) have been previously
published [13,15,16]. Full detail description is available in the Sup-
plemental Material. Prescribed dose for all plans was 50 Gy/5 frac-
tions (fx), with goal 95% planning target volume (PTV) coverage by
95% of prescription dose (47.5 Gy), subject to hard OAR constraints
(Table 2). The PTV was defined as a 5 mm volumetric expansion
upon the gross tumor volume (GTV). If goal PTV coverage could
not be met without violation of hard OAR constraints, then PTV
coverage was sacrificed in accordance with a strict isotoxicity
approach.
Daily online plan adaptation
Our online plan adaptation and plan QA processes have been
previously published [13]. A complete description is available in
the Supplemental Material. Briefly, each patient underwent volu-
metric MRI imaging for setup and localization. The initial/prior
fraction’s plan was loaded onto the daily image and contours were
manually edited, as needed, by physicians. The prior plan was then
assessed on the daily image. If there was either a violation in an
OAR maximum dose constraint or an opportunity for PTV coverage
improvement, a daily adaptive plan was generated. Maximum tar-
get dose was 60 Gy at 15 Gy per fraction, permitting treating physi-
cians to condense the treatment to four fractions if all OAR
constraints could be met. Adaptive plans were evaluated and com-
pared to the prior, non-adaptive plans based on dose to OARs and
PTV coverage without dose accumulation, using a fraction-by-
fraction, strict isotoxicity approach. The superior plan was then
delivered. Any delivered adaptive plan became the default, non-
adaptive plan for the subsequent fraction.
Treatment delivery and cine gating
All treatment fractions were delivered with real-time MR-
guidance including cine-MR gating on the GTV based on the exhale
phase during free breathing. Gating window targets and settings
were selected by physicians and evaluated on each treatment
day. Details of MR-guidance and cine-MR gating, as implemented
at our institution for standard clinical practice, have been previ-
ously published [17]; a complete description is available in Supple-
mental Materials.
Dosimetric and timing data collection
The prospective primary endpoint of the study was feasibility,
defined by delivery of adaptive treatment in <80 min on-table time
for >75% of cases. This endpoint was subjectively chosen based on
study physician anticipation that patients would not tolerate treat-
ments exceeding 80 min. Door-to-door patient treatment, imaging,
physician segmentation, re-planning, and plan QA times were
prospectively recorded at each fraction by treating radiation ther-
apists. Prospectively recorded dosimetry included OAR dose,
cumulative GTV/PTV dose, and projected dose that would have
been delivered by non-adaptive plans. Current technology is insuf-
ficient to reproducibly identify point volumes of deformable OARs
for dose accumulation. GTV/PTV dose accumulation was per-
formed, with detailed description provided in the Supplemental
Materials.
Patient follow-up, quality-of-life metrics, and statistical analysis
Pre-treatment collection of patient data included patient demo-
graphics, baseline Response Evaluation Criteria in Solid Tumors
(RECIST) criteria target tumor measurements of the treated lesion,
and baseline European Organization for Research and Treatment of
Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Ver-
sion 3.0 quality of life (QOL) scores. Patients had planned follow-
up at 6, 12, and 26 weeks post-treatment. Study physicians
prospectively assessed treatment response of treated-lesions using
RECIST at pre-planned time points of three and six months post-
treatment. Disease-free, progression-free, and overall survival
were prospectively assessed at 12 and 26 weeks post-treatment
and subsequently through chart review and routine clinical
appointments. Acute (defined as within six months of therapy
completion) Common Terminology Criteria for Adverse Events
(CTCAE) v4.0 gastrointestinal toxicity was prospectively assessed
at 6, 12, and 26 weeks by clinical research coordinators (CRCs)
through the Washington University clinical trials office. Subse-
quent late toxicities occurring after the six month study period
were rigorously assessed by the treating physicians through rou-
tine clinical care and retrospective chart review. CRCs also prospec-
tively assessed patient-reported QOL scores at zero, six, and 26
weeks post-treatment. Repeated measures analysis was used to
assess for change in QOL scores. Kaplan Meier analysis was used
to estimate local progression-free survival. Statistical analyses
were performed by the study statistician using SAS, Version 9.2
(SAS Institute, Inc., Cary, NC).
Results
Patient and tumor characteristics
Patient demographics and disease characteristics are described
in Table 1. A total of 20 evaluable patients were enrolled and trea-
ted per protocol; ten patients received treatment for hepatic
lesions and ten underwent treatment for non-liver abdominal sites.
Of 20 patients enrolled, 11 had oligometastatic disease, while nine
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had unresectable primary lesions. Median follow-up time from
completion-of-therapy (COT) was 15 months (range 4–22 mos).
Treatment planning and delivery
All initial plans from simulation met hard OAR constraints. All
20 patients completed planned treatment with SMART. A total of
97 fractions were delivered. Seventeen patients received a 5fx
course, while three patients were treated with a condensed course
of 60 Gy/4fx. At time of treatment delivery, a daily adapted plan
was determined to be superior to the initial plan or previously
adapted fraction for 83.5% (81/97) of fractions. All patients
required adaptive planning for 1 fraction. Fig. 1 summarizes the
clinical reasons for plan adaptation for each patient. Overall,
100% of non-liver-abdomen fractions were adapted and 31/47
(66%) of liver fractions benefitted from online adaptation.
The primary endpoint of delivery of adaptive treatment in <80
min for >75% of cases was not met. 52% of fractions were com-
pleted in <80 min and >75% of cases were completed in 90 min
instead of <80. However, SMART remained clinically deliverable,
and all 20 patients completed therapy with median on-table-
time of 79 min/fx (range 36–160 min). On table-time comprised
MR-imaging set up (median 3.5 min, range 1–14 min), time for
physician arrival (median 4 min, range 0–15 min), patient localiza-
tion/shift application (median 2 min, range 0–14 min), median re-
segmentation (median 9 min, range 2–24 min), re-planning (med-
ian 10 min, range 2–24 min), QA (median 4 min, range 1–14 min),
and beam-on time (median 33.5 min, range 16–107 min). If adap-
tation was not required, then the re-segmentation, replanning, and
QA times were zero/not applicable.
Organ-at-risk constraints
Of adapted fractions, 61/81 (75%) were adapted for the primary
purpose of reversing an OAR constraint violation that occurred
when the prior plan was applied to anatomy-of-the-day on treat-
ment days (Fig. 1). Fig. 2 illustrates an example case. Within non-
liver abdomen fractions, 44/50 (88%) required adaptive plan cre-
ation to reverse  1 OAR violations, most often comprising small-
bowel (n = 37). Of liver fractions, 17/47 (36.2%) were adapted to
reverse OAR violations. Severity of OAR violations that would have
occurred without plan adaptation was variable, both in terms of
magnitude by which constraints were violated (Fig. 3) and volume
of OARs that received excess dose (Table 2). Table 2 and Fig. 3 sum-
marize OAR violations. Adaptive plans successfully reversed 100%
of OAR violations.
Target volume coverage and dose escalation
Twenty fractions were adapted with sole intent to increase dose
coverage to 95% of the PTV by the prescribed isodose line (Fig. 1).
These included 6/50 non-liver-abdomen fractions and 14/47 liver
fractions. Target coverage was not necessarily compromised by
plan adaptation to meet organ-at-risk constraints. In 35/61fx
where adaptive plans were required for OAR violation reversal,
improved PTV coverage was simultaneously achieved (example,
Fig. 2). In the other 26fx, PTV dose de-escalation was required to
meet OAR constraints (example, Fig. 4c). However, mean and med-
Table 1
Patient, tumor, and treatment delivery characteristics.
Median age (range) 64 (48–79)
Median tumor size in cm (range) 3.5 (1.6–11)
Median prior chemotherapy regimens (range) 2 (0–5)
Median KPS (range) 90 (80–100)
Liver 10
Colorectal cancer metastasis 4
Primary intra-hepatic cholangiocarcinoma 1
Primary hepatocellular carcinoma 4
Hepatocellular carcinoma metastasis 1
Non-liver abdomen 10
Non-small cell lung cancer adrenal metastasis 2
Recurrent pancreatic adenocarcinoma 3
Primary pancreatic adenocarcinoma 2
Para-aortic lymph node metastasis 3
Total delivered fractions 97
Total adapted fractions (% of total) 81 (83.5)
Delivered liver fractions 47
Adapted liver fractions (%) 31 (47)
Adapted for 1 OAR violation (%) 17 (36.2)
Adapted only to increase PTV coverage (%) 14 (29.8)
Delivered non-liver abdomen fractions 50
Adapted non-liver abdomen fractions (%) 50 (100)
Adapted for 1 OAR violation (%) 44 (88)
Adapted only to increase PTV coverage (%) 6 (12)
Median on-table time in min (range) 79 (36–160)
Median re-contour time in min (range) 9 (2–24)
Median re-plan time in min (range) 10 (1–19)
Median QA time in min (range) 4 (1–14)
Table 2
Hard dose constraints and target volume coverage goals for initial non-adaptive plans and adaptive plans, with recorded organ-at-risk violation metrics for application of initial
plan to the treatment-day anatomy as well as cumulative dose metrics for GTV and PTV coverage by both initial and adaptive plans.
Organ at risk Hard constraint # of PI constraint violations Mean (Std Dev) Median Range
Uninvolved liver (liver – GTV) 700 cm3 < 20 Gy 1 968 cm3 968 cm3 NA
V25Gy < 33% 1 45.21% 45.21% NA
Mean < 20 Gy 1 24.73 Gy 24.73 Gy NA
Stomach max V33Gy < 0.5 cm3 22 3.18 ± 3.49 cm3 1.97 cm3 0.63–13.21 cm3
Duodenum max V35Gy < 0.5 cm3 14 2.41 ± 2.64 cm3 1.09 cm3 0.51–9.11 cm3
Small bowel max V30Gy  0.5 cm3 37 5.48 ± 7.01 cm3 3.72 cm3 0.57–33.91 cm3
Large bowel max V35Gy  0.5 cm3 4 2.31 ± 1.50 cm3 2.23 cm3 0.80–3.97 cm3
Heart/Pericardium V32Gy  15 cm3 5 18.55 ± 2.52 cm3 17.85 cm3 16.39–22.09 cm3
Cord V25Gy < 0.5 cm3 1 0.72 cm3 0.72 cm3 NA













PTV V50 NA 66.3 ± 26.1% 69.3 (0.1–98.9)% 70.4 ± 27.7% 76.7 (15.6–100)%
PTV V47.5 95% 76.2 ± 26.2% 81.6 (0.4–100)% 79.4 ± 24.1% 88.6 (20.7–100)%
GTV V50 100% 81.0 ± 26.8% 91.0 (0–100)% 85.0 ± 21.9% 97.8 (26.0–100)%
GTV V47.5 100% 85.6 ± 24.4% 94.7 (0–100)% 89.6 ± 17.2% 99.3 (33.1–100)%
GTV V45 100% 88.5 ± 23.0% 97.1 (0–100)% 92.2 ± 14.8% 99.6 (39.5–100)%
GTV Max NA 61.0 ± 7.2 Gy 59.4 (43.8–74.1)% 64.1 ± 5.1 Gy 64.6 (54.9–72.7) Gy
GTV Min NA 36.8 ± 14.7 Gy 37.6 (2.0–59.1)% 42.5 ± l3.7 Gy 42.8 (19.3–62.0) Gy
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ian cumulative GTV and PTV dose coverage was superior with
SMART compared to projected non-adaptive SBRT.
Dose escalation beyond 10 Gy/fx, while maintaining hard OAR
constraints, was not feasible for any non-liver-abdomen cases. In
3/10 dose-escalated liver patients, favorable day one anatomy per-
mitted dose escalation beyond 10 Gy/fx and persisted, such that
treatment courses could be condensed to four fractions and fx1
adaptive plans were reused without change for all subsequent frac-
tions (example DVH, Fig. 4d). In this manner, a total of 12/47fx were
dose-escalatedbeyond10 Gy/fx (median 15 Gy/fx). Table 2 provides
complete summary of projected non-adaptive versus adaptive
cumulative GTV and PTV dose. Example cumulative GTV DVH com-
parisons for adaptive versus initial plans are illustrated in Fig. 4.
Toxicity and quality-of-life
We observed zero acute (within six months), treatment-related
CTCAEv.4 Gr3+ toxicities, with all patients accounted for at six-
months’ follow-up. One patient developed an asymptomatic Gr2
gastric-antrum ulcer outside the high-dose field (within the 10–
15 Gy low-dose region), discovered on follow-up imaging 4 mo
after COT. This resolved with proton-pump-inhibitor therapy.
Two patients had Gr4 anemia and thrombocytopenia deemed
unrelated to radiotherapy. These instances were following full-
dose gemcitabine and FOLFIRINOX chemotherapy at 1.5 and 3.5
months post-radiotherapy, respectively. Of note, zero Grade 3 or
higher late toxicities (occurring > 6 mos after RT) were observed,
with 15-month median follow-up.
Patient-reported QOL was prospectively recorded by clinical
research coordinators at zero, six, and 26 weeks follow-up using
the EORTC QLQ-C30. Median global QOL scores were not signifi-
cantly different during treatment and the acute post-therapy win-
dow by repeated measures analysis (Supplemental Fig. 1; P = 0.29).
Single-item QOL scores that might indicate low-level toxicity such
as for diarrhea, constipation, nausea, emesis, appetite, pain or
activity tolerance, were also unchanged.
Fig. 1. Flow diagram of the primary clinical reason for plan adaptation for each study patient. Reasons for adaptation included reversal of organ-at-risk (OAR) violation,
planning target volume (PTV) dose increase, or for both.
Fig. 2. A fraction 1 plan met all organ-at-risk (OAR) constraints based on day 1 anatomy-of-the-day (a). Application of the fx1 plan as the initial plan to fx2 anatomy-of-the-
day for this patient with a para-aortic metastasis (blue colorwash) resulted in small-bowel (green colorwash) constraint violation (b). Daily adaptive planning achieved OAR
constraint violation resolution while also improving planning target-volume (PTV) coverage (c and d).
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Fig. 3. Maximum scaled fractional point-dose (red marks) to constraint volumes of organs-at-risk (OARs) that violated constraints and would have been delivered to OARs in
absence of plan adaptation. Black squares indicate goal OAR constraints over five fractions. Blue circles represent maximum, scaled doses delivered to OARs in the same
patients on fractions that did not require adaptation.
Fig. 4. Cumulative dose delivered to gross tumor volumes (GTV) via adaptive planning versus projected dose delivered by non-adaptive planning. Frames 4a and 4b
demonstrate dose–volume histograms for patients with para-aortic and liver metastases. In 4c, organ-at-risk proximity to a pancreas tumor required adaptive GTV dose de-
escalation for several fractions. In 4d, dose-escalation to a liver tumor beyond 10 Gy/fx was feasible with magnetic-resonance-guidance and a condensed course of 60 Gy/4fx
was delivered using a single, fx1 plan adaptation.
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Tumor control and survival
RECIST local progression-free survival (defined here as stability,
partial response, or complete response of the treated lesion) was
95% and 89.1% by Kaplan Meier analysis at three and six months’
follow-up. At median follow-up of 15 months (range: 7.5–21 mo),
only two patients – both with recurrent, locally advanced pancre-
atic cancer (LAPC) – experienced RECIST progression. At one year,
nine patients had no evidence of active disease and 1-year overall
survival for all-comers was 75% (15/20). Among the 11 patients
with oligometastatic disease at enrollment, 1-year overall survival
was 91% (10/11) and 1-year systemic progression-free survival was
45%. Notably, among patients with unresectable primaries, the two
patients treated for primary LAPC were both alive without progres-
sion at 50 and 56 weeks follow-up.
Discussion
This is the first prospective, clinical study of stereotactic MR-
guided online-adaptive radiotherapy (SMART) and of daily
online-adaptive external-beam radiotherapy. In this Phase I trial,
we evaluated the feasibility and safety of SMART for oligometa-
static and unresectable primary abdominal malignancies using
ablative doses. The secondary study intent was to characterize
potential dosimetric and clinical advantages of this approach
within the abdomen for both OAR sparing and target volume cov-
erage. While our primary feasibility endpoint of treatment delivery
for >75% of fractions in under 80 min was not met, our results sup-
port SMART as an approach that is clinically deliverable, dosimet-
rically advantageous, and results in minimal gastrointestinal
toxicity.
Our primary endpoint was unmet. Nevertheless, all patients
completed therapy as planned, with median on-table time of 79
min. Our feasibility goal of delivery of >75% of fractions in <80
min was chosen because study authors anticipated longer treat-
ment times would not be tolerated by patients or supported by
clinic workflow. However, this pre-determined limit of tolerance
was inaccurate, as demonstrated by all patients completing treat-
ment as delivered. Since study completion, process changes includ-
ing more focused daily re-segmentation, improved software tools,
improved tumor and OAR instructions for covering physicists/-
physicians, and consolidation of QA procedures have decreased
this time. While time required is longer than typical SBRT fractions,
it matches that of other radiation therapy procedures, such as
brachytherapy, and is similar to initial implementations of inten-
sity modulated radiotherapy (IMRT) and robotic SBRT [18–21]. It
is reasonable to assume that organized efforts to advance MR-
IGRT technology, including development of MR-guided linear-
accelerator systems and ongoing improvements in auto-
segmentation of normal structures, will reduce future treatment
times considerably [22–25].
We also observed that SMART was advantageous for OAR spar-
ing. Online-adaptive planning revealed frequent, unintended OAR
constraint violations that would have occurred in non-adaptive
fractions (63%), and all successfully were reversed with SMART.
This high number of non-adaptive OAR violations observed is
consistent with previous reports of interfractional organ motion
and matches the rate predicted by our simulation study using
identical MR-IGRT technology [10,14]. It is possible that not all
OAR violations prevented by SMART would have been clinically
meaningful. However, prior studies delivering high dose therapy
to the abdomen while comparatively accounting for tumor
motion resulted in prohibitive levels of gastrointestinal toxicity
[26]. By comparison, to date, our observed Gr3+ toxicity rate
was zero, despite ablative doses. Importantly, patient-reported
QOL scores – including specific scores for nausea, pain, and other
indicators of bowel toxicity – were also not adversely impacted
by therapy, suggesting that any low-level, unreported gastroin-
testinal toxicity was clinically insignificant. Coupled together,
these factors suggest that the observed dosimetric benefits of
SMART for OAR sparing may translate to reduced toxicity,
although further study is needed.
Adaptive planning also increased tumor dose in a majority of
fractions and improved overall mean/median target coverage.
Notably, in 100% of fractions where patient anatomy-of-the-day
was favorable and did not result in OAR constraint violation, target
coverage improvement was achieved by adaptive planning. Dose
escalation beyond 10 Gy per fraction was possible in a subset of
three patients, to up to 15 Gy per fraction, resulting in a higher
BED. This small subset of patients uniquely had hepatic lesions
located >2 cm from the luminal gastrointestinal tract proximity,
enabling consistent delivery of escalated dose with less overall risk
to OARs. Our institutional practice has since shifted to use MR-
localization and cine gating without adaptation for more central
hepatic lesions. It may be unnecessary to escalate dose beyond
50 Gy in 5 fractions for oligometastatic lesions, although achieve-
ment of an increased BED has been shown to be of utility in some
primary malignancies [3,4]. For all comers, local control was excel-
lent at 6 months, with both cases of treated-tumor progression
occurring in the setting of recurrent pancreatic cancer, which car-
ries a particularly poor prognosis [27]. Without use of online-
adaptive planning, dose to abdominal sites has historically been
limited to sub-ablative levels due to normal tissue toxicity [8].
While data on the utility of radiotherapy for certain primary
abdominal malignancies, such as LAPC, may be mixed, local control
of oligometastatic disease does correlate with increased dose
[7,28–30]. However, local control benefit of dose escalation
enabled by SMART was not the focus of this feasibility trial and
requires future study.
The application of SMART to enable oligometastasis ablation
with minimal toxicity is supported by our cohort. Of our oligome-
tastatic patients, 8/11 were alive without toxicity or advancement
of systemic disease state at last follow-up. Ongoing randomized
trials aim to confirm benefit of an ablative approach for the oligo-
metastatic state [31,32]. If benefits are demonstrated, SMART may
be an optimal strategy to maximize the therapeutic ratio for oligo-
metastatic patients.
We acknowledge several limitations to our study. First, current
technology is insufficient to reproducibly identify point volumes of
deformable OARs including bowel for accurate calculation of
cumulative dose. Our fraction-by-fraction isotoxicity approach,
while favorably guaranteeing that no point-volume of OAR will
exceed dose constraints, may be excessively conservative. OAR
dose accumulation and delineation of ‘‘true” abdominal dose con-
straints based on the accurate inter- and intra-fraction imaging
information that real-time MR-guidance affords are of future
research interest.
Similarly, although our use of 2D-cine gating permitted target
monitoring during treatment, it is possible that unobserved intra-
fraction OAR motion degrades dosimetric benefits achieved by
adaptation. Use of three-dimensional volumetric MR-gating may
be possible in the future and could mitigate this concern. Efforts to
manage motion and adapt plans based on intra-fraction imaging
feedback may represent a future gold-standard but remain far from
clinical implementation [33,34]. Additionally, the PTVmargins cho-
sen for this study were conservative, at 0.5 cm from the GTV, an
expansion that was selected to match that of typical CT-guided
SBRT, in order to avoid excessive departures from standard-of-
care SBRT practice in this first application of SMART. However, given
the soft tissue visualization improvements ofMR-IGRT, reduced PTV
margin size has nowbeen applied in selectMR-guided scenarios and
is of ongoing interest in future studies [35].
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In summary, we found that SMART remains clinically deliver-
able, safe, and dosimetrically advantageous compared to non-
adaptive SBRT. By permitting PTV dose escalation and/or concomi-
tant sparing of normal tissues, SMART improves the therapeutic
ratio of abdominal SBRT. A randomized controlled Phase II trial is
now open to directly compare toxicity rates between SMART and
non-adaptive MR-localized SBRT to abdominal oligometastatic/
unresectable primary disease.
Funding
This study was funded by an industry research grant from
ViewRay, Inc. The funding source had no role or involvement in
study design, data collection, data analysis, interpretation of
results, the writing of the manuscript, or the choice to submit
the manuscript for publication. The content is solely the responsi-
bility of the authors.
This publication was additionally supported by the Washington
University Institute of Clinical and Translational Sciences grant
UL1T2000448 from the National Center for Advancing Transla-
tional Sciences (NCATS). The content is solely the responsibility
of the authors and does not necessarily represent the official views
of the NIH.
Conflict of interest statement
A. Curcuru, Dr. Michalski, Dr. DeWees report no conflicts of
interest related to or outside the submitted work. Dr. Olsen reports
grants, personal fees and non-financial support from ViewRay, Inc,
during the conduct of the study. Dr. Henke reports grants from
ViewRay, Inc., during the conduct of the study, and other from
ViewRay, Inc. outside the submitted work. Dr. Kashani reports
grants from ViewRay, Inc., during the conduct of the study. Dr.
Green and Dr. Bradley report personal fees and other from View-
Ray, Inc. outside the submitted work. Dr. Robinson reports grants,
personal fees and non-financial support from Varian Medical Sys-
tems, personal fees and non-financial support from ViewRay, other
from Radialogica, grants from Elekta, non-financial support from
DFINE, outside the submitted work. Dr. Mutic reports grants and
personal fees from ViewRay, Inc, grants and other from Varian
Medical Systems, other from TreatSafely, LLC, other from Radialog-
ica, LLC, outside the submitted work. Dr. Parikh reports grants from
Philips Healthcare, grants and other from Varian Medical Systems,
other from Holaira, Inc, other fromMedtronic/Covidien, outside the
submitted work.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.radonc.2017.11.
032.
References
[1] Timmerman R, Papiez L, McGarry R. Extracranial stereotactic radioablation:
results of a phase I study in medically inoperable stage I non-small cell lung
cancer. Chest 2003;124:1946–55.
[2] Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body
radiation therapy in multiple organ sites. J Clin Oncol 2007;25:947–52. https://
doi.org/10.1200/JCO.2006.09.7469.
[3] Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic
hypofractionated high-dose irradiation for stage I nonsmall cell lung
carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional
study. Cancer 2004;101:1623–31. https://doi.org/10.1002/cncr.20539.
[4] Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, et al. A
collaborative analysis of stereotactic lung radiotherapy outcomes for early-
stage non-small-cell lung cancer using daily online cone-beam computed
tomography image-guided radiotherapy. J Thorac Oncol 2012;7:1382–93.
https://doi.org/10.1097/JTO.0b013e318260e00d.
[5] Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ,
et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy
for liver metastases. J Clin Oncol 2009;27:1572–8. https://doi.org/10.1200/
JCO.2008.19.6329.
[6] Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A,
et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic
body radiotherapy for patients with locally advanced unresectable pancreatic
adenocarcinoma. Cancer 2015;121:1128–37. https://doi.org/10.1002/
cncr.29161.
[7] Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, et al.
Stereotactic body radiotherapy for multisite extracranial oligometastases: final
report of a dose escalation trial in patients with 1–5 sites of metastatic disease.
Cancer 2012;118:2962–70. https://doi.org/10.1002/cncr.26611.
[8] Crane CH. Hypofractionated ablative radiotherapy for locally advanced
pancreatic cancer. J Radiat Res 2016;57:i53–7. https://doi.org/10.1093/jrr/
rrw016.
[9] Singh AK, Tierney RM, Low DA, Parikh PJ, Myerson RJ, Deasy JO, et al. A
prospective study of differences in duodenum compared to remaining small
bowel motion between radiation treatments: implications for radiation dose
escalation in carcinoma of the pancreas. Radiat Oncol 2006;1:33. https://doi.
org/10.1186/1748-717X-1-33.
[10] Liu F, Erickson B, Peng C, Li XA. Characterization and management of
interfractional anatomic changes for pancreatic cancer radiotherapy. Int J
Radiat Oncol Biol Phys 2012;83:e423–9. https://doi.org/10.1016/j.
ijrobp.2011.12.073.
[11] Noel CE, Parikh PJ, Spencer CR, Green OL, Hu Y, Mutic S, et al. Comparison of
onboard low-field magnetic resonance imaging versus onboard computed
tomography for anatomy visualization in radiotherapy. Acta Oncol 2015:1–9.
https://doi.org/10.3109/0284186X.2015.1062541.
[12] Mutic S, Dempsey JF. The ViewRay system: magnetic resonance-guided and
controlled radiotherapy. Semin Radiat Oncol 2014;24:196–9. https://doi.org/
10.1016/j.semradonc.2014.02.008.
[13] Acharya S, Fischer-Valuck BW, Kashani R, Parikh P, Yang D, Zhao T, et al. Online
magnetic resonance image guided adaptive radiation therapy: first clinical
applications. Int J Radiat Oncol Biol Phys 2016;94:394–403. https://doi.org/
10.1016/j.ijrobp.2015.10.015.
[14] Henke L, Kashani R, Yang D, PhD TZ, PhD OG, PhD LO, et al. Simulated online
adaptive magnetic resonance-guided stereotactic body radiation therapy for
the treatment of oligometastatic disease of the abdomen and central thorax:
characterization of potential advantages. Int J Radiat Oncol Biol Phys
2016;96:1078–86. https://doi.org/10.1016/j.ijrobp.2016.08.036.
[15] Wooten HO, Green O, Yang M, DeWees T, Kashani R, Olsen J, et al. Quality of
intensity modulated radiation therapy treatment plans using a 60Co magnetic
resonance image guidance radiation therapy system. Int J Radiat Oncol Biol
Phys 2015;92:771–8. https://doi.org/10.1016/j.ijrobp.2015.02.057.
[16] Hu Y, Rankine L, Green OL, Kashani R, Li HH, Li H, et al. Characterization of the
onboard imaging unit for the first clinical magnetic resonance image guided
radiation therapy system. Med Phys 2015;42:5828–37. https://doi.org/
10.1118/1.4930249.
[17] Green OL. Implementation of real-time, real-anatomy tracking and radiation
beam control on the first MR-IGRT clinical system, vol. 93; 2015.
[18] Mayadev J, Qi L, Lentz S, Benedict S, Courquin J, Dieterich S, et al. Implant time
and process efficiency for CT-guided high-dose-rate brachytherapy for cervical
cancer. Brachytherapy 2014;13:233–9. https://doi.org/10.1016/j.
brachy.2014.01.004.
[19] Radford Evans D-A, Meyer T, Angyalfi S, Husain S, Kay I, Dunscombe P.
Enhanced efficiency and ergonomics of an intraoperative automated prostate
brachytherapy delivery technique. Brachytherapy 2007;6:254–7. https://doi.
org/10.1016/j.brachy.2007.08.002.
[20] Chao KS, Majhail N, Huang CJ, Simpson JR, Perez CA, Haughey B, et al.
Intensity-modulated radiation therapy reduces late salivary toxicity without
compromising tumor control in patients with oropharyngeal carcinoma: a
comparison with conventional techniques. Radiother Oncol 2001;61:275–80.
[21] Whyte RI, Crownover R, Murphy MJ, Martin DP, Rice TW, DeCamp MM, et al.
Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial.
Ann Thorac Surg 2003;75:1097–101. https://doi.org/10.1016/S0003-4975(02)
04681-7.
[22] Raaymakers BW, de Boer JCJ, Knox C, Crijns SPM, Smit K, Stam MK, et al.
Integrated megavoltage portal imaging with a 1.5 T MRI linac. Phys Med Biol
2011;56:N207–14. https://doi.org/10.1088/0031-9155/56/19/N01.
[23] Lagendijk JJW, van Vulpen M, Raaymakers BW. The development of the MRI
linac system for online MRI-guided radiotherapy: a clinical update. J Intern
Med 2016;280:203–8. https://doi.org/10.1111/joim.12516.
[24] Kerkmeijer LGW, Fuller CD, Verkooijen HM, Verheij M, Choudhury A,
Harrington KJ, et al. The MRI-linear accelerator consortium: evidence-based
clinical introduction of an innovation in radiation oncology connecting
researchers, methodology, data collection, quality assurance, and technical
development. Front Oncol 2016;6:215. https://doi.org/
10.3389/fonc.2016.00215.
[25] Altman MB, Kavanaugh JA, Wooten HO, Green OL, DeWees TA, Gay H, et al. A
framework for automated contour quality assurance in radiation therapy
including adaptive techniques. Phys Med Biol 2015;60:5199–209. https://doi.
org/10.1088/0031-9155/60/13/5199.
[26] Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, et al. Phase-II
study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.
L. Henke et al. / Radiotherapy and Oncology 126 (2018) 519–526 525
Radiother Oncol 2005;76:48–53. https://doi.org/10.1016/j.
radonc.2004.12.022.
[27] Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al.
Gemcitabine alone or with cisplatin for the treatment of patients with
locally advanced and/or metastatic pancreatic carcinoma: a prospective,
randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale.
Cancer 2002;94:902–10. https://doi.org/10.1002/cncr.10323.
[28] Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P, et al.
Effect of chemoradiotherapy vs chemotherapy on survival in patients with
locally advanced pancreatic cancer controlled after 4 months of gemcitabine
with or without erlotinib: the LAP07 randomized clinical trial. JAMA
2016;315:1844–53. https://doi.org/10.1001/jama.2016.4324.
[29] Krishnan S, Chadha AS, Suh Y, Chen H-C, Rao A, Das P, et al. Focal radiation
therapy dose escalation improves overall survival in locally advanced
pancreatic cancer patients receiving induction chemotherapy and
consolidative chemoradiation. Int J Radiat Oncol Biol Phys 2016;94:755–65.
https://doi.org/10.1016/j.ijrobp.2015.12.003.
[30] Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, et al. Stereotactic
single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin
Oncol 2001;19:164–70.
[31] NRG Oncology. Standard of care therapy with or without stereotactic
radiosurgery and/or surgery in treating patients with limited metastatic.
Breast Cancer 2017. 1–1.
[32] Verheul H. Chemotherapy and maximal tumor debulking of multi-organ
colorectal cancer metastases (ORCHESTRA) 2017:1–1
[33] Glitzner M, Fast MF, de Senneville BD, Nill S, Oelfke U, Lagendijk JJW, et al.
Real-time auto-adaptive margin generation for MLC-tracked radiotherapy.
Phys Med Biol 2017;62:186–201. https://doi.org/10.1088/1361-6560/62/1/
186.
[34] Kontaxis C, Bol GH, Lagendijk JJW, Raaymakers BW. A new methodology for
inter- and intrafraction plan adaptation for the MR-linac. Phys Med Biol
2015;60:7485–97. https://doi.org/10.1088/0031-9155/60/19/7485.
[35] Acharya S, Fischer-Valuck BW, Mazur TR, Curcuru A, Sona K, Kashani R, et al.
Magnetic resonance image guided radiation therapy for external beam
accelerated partial-breast irradiation: evaluation of delivered dose and
intrafractional cavity motion. Int J Radiat Oncol Biol Phys 2016;96:785–92.
https://doi.org/10.1016/j.ijrobp.2016.08.006.
526 SMART for abdominal oligometastases
